



# Nucleotide Metabolism

By Jessica Shuster


# Overview of Nucleotides

- Components
  - Nitrogenous base (purine/pyrimidine)
  - Pentose sugar (ribose/deoxyribose)
  - Phosphate group(s)
- Functions
  - Building blocks of DNA/RNA
  - Coenzymes (NAD<sup>+</sup>, FAD)
  - Energy transfer (ATP, GTP)
  - Second messengers (cAMP, cGMP)
  - Allosteric regulators (ATP, ADP, AMP)




# Structure of Purines and Pyrimidines

## Purines



Adenine (A)




Guanine (G)


Pure As Gold

CUT the pyramid

## Pyrimidines



Cytosine (C)




Thymine (T)




# De Novo Purine Biosynthesis

- Uses **amino acids** as precursors to produce nucleotides
- Occurs primarily in the **liver**
- Requires at least **six high-energy bonds (ATP)** per purine molecule synthesized
- Goal is to create **inosine monophosphate (IMP)**, and IMP turns into adenine or guanine
- 11 step process !




# Sources of Atoms in Purine Rings






- Amino acids necessary for **pur**ine synthesis (cats **pur**r until they **GAG**):
  - **G**lycine
  - **A**spartate
  - **G**lutamine

# Step 1: Creating PRPP

- 5-Phosphoribosyl-1-pyrophosphate (PRPP) is an activated form of ribose used to initiate purine biosynthesis
- Synthesized from **ribose 5-phosphate** (produced from glucose via the pentose phosphate pathway) and **ATP** by the enzyme **PRPP synthetase**
- PRPP is used in **both** purine and pyrimidine biosynthesis !




# Step 2: Rate Limiting Step !






- PRPP reacts with glutamine to form 5'-phosphoribosyl-1'-amine
- Catalyzed by glutamine phosphoribosylamidotransferase (GPAT)
  - This enzyme is highly regulated, making this step the committed/rate limiting step of purine biosynthesis

# 9 more steps to get to IMP!










# IMP to AMP

## Formation of Adenylosuccinate

- Aspartate is added to IMP
- Enzyme: **Adenylosuccinate synthetase**
- Requires **GTP** as the energy source

## Formation of AMP

- **Fumarate** is released from adenylosuccinate
- Enzyme: **Adenylosuccinate lyase**



# IMP to GMP


## Formation of XMP

- The hypoxanthine base of IMP is oxidized to xanthine
- Enzyme: **IMP dehydrogenase**

## Conversion of XMP to GMP

- **Glutamine** donates an amide nitrogen to XMP
- Enzyme: **GMP synthetase**
- Requires **ATP** for energy

# Purine Synthesis Regulation



## Regulation of PRPP synthetase

- Inhibitors: GDP (oxypurine), ADP (aminopurine)

## Regulation of GPAT

- Inhibitors: GMP, AMP
- Activators: PRPP, glutamine


## Regulation of IMP dehydrogenase

- Inhibited by GMP
- Activated by high ATP

## Regulation of Adenylosuccinate synthetase


- Inhibited by AMP
- Activated by high GTP

# Purine Salvage Pathways



- Allows free bases, nucleosides, and nucleotides to be easily interconverted
- Requires significantly less energy compared to de novo synthesis
- Major form of nucleotide generation for specific cell types like **lymphocytes**
- Key enzymes
  - APRT
  - HGPRT
  - Adenosine deaminase (ADA)
  - Purine nucleoside phosphorylase (PNP)

# Lesch-Nyhan Syndrome




- Defective purine salvage
- HGPRT deficiency
- **Decreased GMP and IMP formation**
- **Compensatory increase in purine synthesis (increased GPAT) leads to excess uric acid production!**

## HGPRT:


- **H**yperuricemia
- **G**out
- **P**issed off (aggression, self-mutilation)
- **R**ed/orange crystals in urine
- **T**ense muscles (dystonia)

# Adenosine Deaminase (ADA) Deficiency




- Deoxyadenosine (dA) and its toxic derivatives accumulate in blood and immune cells
- Elevated dATP levels inhibit ribonucleotide reductase, impairing DNA synthesis
- Severe dysfunction of both T cells and B cells
- Causes Severe Combined Immunodeficiency (SCID):
  - Increased susceptibility to infections
  - Failure to thrive and developmental delays

# PNP Deficiency



- Inosine and guanosine accumulation
- Toxic effects of accumulated nucleosides selectively impair T-cell function, while B-cell function remains near normal
- Increased susceptibility to infections due to loss of T-cell function




# Purine Degradation

Degradation pathways:

- AMP  $\rightarrow$  IMP  $\rightarrow$  inosine  $\rightarrow$  uric acid
- GMP  $\rightarrow$  guanine  $\rightarrow$  xanthine  $\rightarrow$  uric acid


most of uric acid is excreted in urine !





# Gout

- Increased levels of uric acid in blood (hyperuricemia)
- Due to overproduction (10%) or underexcretion (90%) of uric acid
- Deposits of monosodium urate (MSU) crystals in joints causing an inflammatory response
- Treated with Allopurinol (hypoxanthine analogue), which inhibits Xanthine oxidase → decreased uric acid production



# De Novo Pyrimidine Biosynthesis

Glutamine + CO<sub>2</sub> + 2ATP

CPS-II

UTP   PRPP

Carbamoyl phosphate

Aspartate

Orotate


PRPP

CO<sub>2</sub>


UMP

- Pyrimidine bases are synthesized **first** and then attached to **ribose-5-phosphate** from PRPP
- Entire pathway occurs in the **cytosol**
- **CPSII** is the key regulatory enzyme
- Synthesis of any pyrimidine nucleotide begins with the formation of **uridine monophosphate (UMP)**

# Sources of Atoms in a Pyrimidine Ring




# Step 1: Formation of Carbamoyl Phosphate




- Glutamine + Bicarbonate + ATP → Carbamoyl Phosphate
- Enzyme: Carbamoyl Phosphate Synthetase II (CPSII)
- Occurs in the cytosol (unlike CPSI in the mitochondria)


## Step 2: Addition of Aspartate




# Step 3: Ring Closure



# Step 4: Oxidation to Orotic Acid




# Step 5: Addition of PRPP






# Step 6: Formation of UMP !



# Conversion of UMP to CTP




## Phosphorylation of UMP to UTP

- UMP (uridine monophosphate) is phosphorylated to UTP (uridine triphosphate) through nucleotide kinases

## Synthesis of CTP

- An amine group from glutamine is added to UTP forming CTP (cytidine triphosphate)
- Enzyme: CTP synthetase

# Pyrimidine Synthesis Regulation




## Regulated Step

- CPSII is the key regulatory enzyme in pyrimidine synthesis.

## Allosteric Regulation

- Inhibited by **UTP** (high pyrimidine levels)
- Activated by **PRPP** (low pyrimidine levels)

# Pyrimidine Salvage Pathways




## Pyrimidine Nucleoside Phosphorylase

- Converts pyrimidine bases to nucleoside monophosphates
- Preference:
  - Uracil is the preferred substrate, and this enzyme is sometimes called **uridine phosphorylase**
  - Cytosine is also utilized, though with lower efficiency
  - Thymine is poorly utilized, as the enzyme has very low affinity for it

## Thymine Phosphorylase


- Converts **thymine** to a **deoxyribonucleoside** (adds a **deoxyribose** residue)
- Has a high affinity for thymine, facilitating its salvage into the nucleotide pool

# Pyrimidine Degradation



- Pyrimidines are broken down into soluble, non-problematic end products
- Degradation products, such as  $\beta$ -alanine and  $\beta$ -aminoisobutyrate, are safely excreted or metabolized
- Unlike purines, pyrimidine degradation **does not** pose health risks like gout

# Production of Deoxyribonucleotides



- For DNA synthesis, ribose must be reduced to **deoxyribose** at the diphosphate level
- Enzyme: **Ribonucleotide reductase**
- Cofactor: **Thioredoxin**
- **Deoxyribonucleoside diphosphates (dNDPs)** are produced, which are further phosphorylated to triphosphates (dNTPs) for DNA synthesis
- **ATP (+)** and **dATP (-)** regulate activity

WOOCLAP!

